Search clinical trials for: free combination of beclomethasone dipropionate 100µg Formoterol fumarate 6µg

Total 194 results

Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Childhood Asthma

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
Chiesi Farmaceutici S.p.A.

Active, not recruiting

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (FORCE2)

Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

Bronchial Asthma

Poland, Ukraine
University Hospital, Antwerp
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Triple in Asthma Dose Finding (Triskel)

Asthma

Bulgaria, Germany, Hungary, Italy, Poland, United Kingdom
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Asthma
Hull University Teaching Hospitals NHS Trust
Chiesi Farmaceutici S.p.A.

Completed

Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United Kingdom
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Asthma
Alfredo Antonio Chetta
University of Parma

Completed

The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.

Chronic Obstructive Pulmonary Disease

Italy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Chronic Obstructive Pulmonary Disease

France
Zhujiang Hospital

Unknown

Small Airways Evaluation and Treatment

Pulmonary Disease，Chronic Obstructive;

China
The First Affiliated Hospital of Guangzhou Medical...
Guangdong Provincial Hospital of Traditional Chinese Medicine; Tongji Hospital and other collaborators

Not yet recruiting

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (CC-ICS)

Cough

China
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old

Asthma

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Functional Respiratory Imaging Study (FRI) (FRI)

Chronic Obstructive Pulmonary Disease

Belgium, Hungary
Research in Real-Life Ltd
Chiesi Farmaceutici S.p.A.

Completed

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management (Fos/Ser_switch)

Asthma

United Kingdom
PARZIBUT Gilles

Not yet recruiting

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care (TRIMICU)

COPD Exacerbation
Chiesi Farmaceutici S.p.A.

Completed

Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children (PAED2/FRESH)

Asthma

Spain, France, Romania, Bulgaria, Germany, Hungary, Italy, Poland, Russian Federation, Slovakia, Ukraine
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
Chiesi Farmaceutici S.p.A.

Terminated

Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients (STORM)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

Chronic Obstructive Pulmonary Disease | Asthma
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old (PAED1)

Asthma

Denmark
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Chiesi Farmaceutici S.p.A.

Completed

Functional Respiratory Imaging Study (DARWiIN)

Chronic Obstructive Pulmonary Disease

Belgium, Hungary
Chiesi SAS
Kappa Santé

Recruiting

Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study (TriNEXT)

COPD

France
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old (PAED4)

Asthma in Children

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma (FORTE)

Asthma

Ukraine, Bulgaria, Italy
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
Chiesi Farmaceutici S.p.A.

Completed

Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children (PAED3)

Asthma

Poland, Ukraine
Università degli Studi di Brescia

Completed

Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma (FORTINO)

Bronchial Asthma
UPECLIN HC FM Botucatu Unesp
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 (TRIVID)

Covid19

Brazil
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada
Chiesi Farmaceutici S.p.A.

Withdrawn

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

COPD
Chiesi Farmaceutici S.p.A.

Completed

Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

Asthma

Italy
Kindeva Drug Delivery

Completed

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

Asthma

United States
Erasmus Medical Center
Chiesi Farmaceutici S.p.A.

Terminated

Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial (FORZA)

Bronchiectasis

Netherlands
Università degli Studi di Ferrara

Completed

Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma

Asthma

Italy
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Chronic Obstructive Pulmonary Disease

Hungary
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms

Bronchial Asthma

Poland, Ukraine
Chiesi Farmaceutici S.p.A.

Completed

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)

Asthma

Poland
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Chronic Obstructive Pulmonary Disease

United States, Peru, South Africa, Argentina, Mexico, Brazil, Chile, Colombia, Venezuela
Brigham and Women's Hospital

Completed

Replication of the P04334 Asthma Trial in Healthcare Claims Data

Asthma

United States
Consorzio Futuro in Ricerca

Completed

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (PMC-101-APT)

Asthma | COPD

Italy
AstraZeneca

Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

COPD Patients

United States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico

3

Subscribe